Adial Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for addiction, particularly Alcohol Use Disorder (AUD). Their lead investigational drug candidate, AD04, is a genetically targeted serotonin-3 receptor antagonist designed to treat AUD in patients with specific genetic profiles. This approach is complemented by a proprietary companion diagnostic genetic test that identifies these target genotypes, allowing for a more personalized treatment strategy. The company emphasizes the importance of non-abstinence-based therapies, reflecting a shift in the treatment paradigm for addiction.

The development pipeline at Adial Pharmaceuticals includes multiple stages, from discovery to Phase 3 clinical trials. During the discovery phase, researchers identify and screen potential drug candidates for their efficacy and safety through in vitro and in vivo experiments. Once a lead molecule is selected, it undergoes pre-clinical studies to further assess its potential before advancing to human trials. Phase 1 and 2 studies focus on evaluating safety and effectiveness in healthy volunteers and patients, respectively, while Phase 3 trials are designed to confirm the drug's efficacy and safety in a larger patient population. This structured approach underscores Adial's commitment to rigorous scientific evaluation and regulatory compliance in bringing new therapies to market.

United States

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test.

Psychological Diseases

Adial Pharmaceuticals

Alcohol use disorder

<p class="font_7">AD04, uses a novel mode of action that involves genetic screening with a companion diagnostic genetic test prior to treatment and is designed to reduce cravings for alcohol to effectively curb alcohol intake, without the requirement of abstinence prior to or during treatment. Our product candidate is intended to be easy to use since it is administered orally, currently on a twice daily basis and with a once-a-day tablet planned as part of the product’s life cycle management</p>

Adial Pharmaceuticals

Company Details